Cleveland provider earns HIMSS Davies Award

The MetroHealth System of Cleveland, Ohio, has been named a 2015 HIMSS Enterprise Davies Award recipient.

HIMSS has been awarding the Nicholas E. Davies Award of Excellence since 1994, recognizing the outstanding achievement of organizations that have utilized health IT to substantially improve patient outcomes while achieving return on investment. 

MetroHealth has used IT to improve care outcomes for its diabetic population, double the number of HIV and HCV screenings for at-risk patients and reduce drug-resistant infections for a return on investment of nearly $8 million.

"As an integrated care delivery network serving patients regardless of their ability to pay, MetroHealth's commitment to prevention and chronic disease management is critical to avoid hospitalizations and reduce costs," said Jonathan French, director of quality and patient safety at HIMSS North America. "What many organizations call 'soft return on investment' associated with improved patient outcomes has a real impact on the bottom line for MetroHealth."

MetroHealth will be recognized at the 2016 HIMSS Conference & Exhibition, February 29-March 4, 2016, in Las Vegas.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.